Italy Self-Monitoring Blood Glucose Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.20 Billion |
| Market Size (2029) | USD 1.30 Billion |
| CAGR (2024 - 2029) | 5.92 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Italy Self-Monitoring Blood Glucose Devices Market Analysis
The Italy Self-Monitoring Blood Glucose Devices Market size is estimated at USD 1.20 billion in 2024, and is expected to reach USD 1.30 billion by 2029, growing at a CAGR of 5.92% during the forecast period (2024-2029).
The first year since its inception, the COVID-19 pandemic was responsible for premature deaths, particularly among older individuals. Italy was the first country in Europe affected by COVID-19. Italy was among the countries with the highest mortality rates. Most people who died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies confirmed that chronic diseases like diabetes were associated with adverse outcomes in COVID-19 patients. The pandemic highlighted opportunities for continuing and expanding innovations in the delivery of diabetes care through virtual consultations between healthcare providers and people with diabetes and the use of diabetes technology. Routine diabetes management was essential to mitigate the risk of adverse health outcomes and severe COVID-19 in diabetes patients; however, the pandemic contributed to disruptions in diabetes management.
Blood glucose monitoring increases patients' awareness of glucose values, which supports healthy lifestyle choices. Blood glucose monitoring values help provide feedback and guidance on how to make health behavior changes when needed. Continued elevation in blood glucose levels in diabetes patients can contribute to progressive complications such as renal, nerve, and ocular damage. Appropriate and timely monitoring of blood glucose allows the successful management of out-of-range blood glucose levels, minimizing diabetic-related health complications.
Innovative technologies, such as digital health apps that display and summarize individual blood glucose measurements and incorporate additional relevant data such as insulin doses, meals and snacks, and physical activity, can further support self-management while decreasing disease burden and benefiting overall diabetes care. Integration of blood glucose monitoring with insulin calculators, automated insulin titration software, and remote coaching are further developments that provide patients with poorly controlled diabetes with the additional support needed to improve critical outcomes, thereby enhancing market prospects in the years to come.
Italy Self-Monitoring Blood Glucose Devices Market Trends
Rising Diabetes Prevalence in Italy
The diabetes population in Italy is expected to grow by about 0.57% over the forecast period.
According to the International Diabetes Federation's reports, the prevalence of diabetes in adults in Italy was approximately 9.9%. The Italian health system is highly decentralized, with most administrative and organizational powers held by the regions. The National Diabetes Plan defines priorities and provides guidelines to improve the quality of diabetes care with a patient-centered focus. Regional and local authorities are responsible for its implementation, which varies among the 20 regions. Government policies play a critical role in improving the quality and safety of healthcare in a country at almost all levels of authority-state and local. Policy, systems, and environmental changes are essential elements of a long-term plan to prevent chronic diseases like diabetes.
Self-monitoring is a commitment that many diabetic patients make to manage their condition. The blood glucose levels help the patients and doctors modify their diet, lifestyle, insulin therapy, and medications to help their blood sugar return to normal. With newer innovations in medical technology, glucometers these days have highly sensitive strips and sensors that can detect every component of blood accurately, close to lab results.
The Italian National Healthcare Service (NHS) is ensuring universal coverage for all citizens. People living with diabetes have access, with no out-of-pocket expenditure, to all the medicines, devices, and medical services they need. Overall, Italy has a well-developed system of diabetes care, with numerous diabetes centers throughout the country and free treatment at the point of delivery.
The World Health Assembly Resolution recommended the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO advising the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and the aforementioned factors.
The Test Strips Segment holds the highest market share in the current year
The test strip segment held the highest market share of about 80% in the current year.
Blood glucose test strips are small, disposable strips and are a key component of blood glucose testing. When blood is placed on the test strip, it reacts with a chemical called glucose oxidase, producing gluconic acid from the glucose in the blood. At the other end of the test strip, the meter transfers a current to the strip. The test strip has electric terminals, which allow the meter to measure the current between the terminals. The current between the terminals changes depending on the level of gluconic acid that has been produced. The blood glucose meter then uses an algorithm to work out the blood glucose level based on the difference in current.
The growth in market share of test strips is expected to be higher than that of glucose meters because of the difference in use-case frequency. The glucometer is a one-time purchase; test strips, on the other hand, are a continuous investment as a test strip needs to be disposed of after one use, causing a recurrent cost impact. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost during the same time frame,
Italian law regulates the clinical care of people with diabetes and creates a framework involving medical organizations, prevention programs, personnel training, and legal protection. The National Health Program is structured into essential levels of assistance that can be defined differently in the various regions. The National Health Program is structured into LEAs (essential levels of assistance). LEAs define all the medical assistance modalities offered by the INHS to citizens, with or without partial contributions based on a patient's income. Such reimbursement policies and the aforementioned factors are expected to drive the market over the forecast period.
Italy Self-Monitoring Blood Glucose Devices Industry Overview
The Italian self-monitoring blood glucose device market is fragmented, with few significant and other generic players. Manufacturers like Abbott, LifeScan, Roche, Ascensia, etc. occupy a major share.
Italy Self-Monitoring Blood Glucose Devices Market Leaders
-
Roche Diabetes Care
-
Abbott Diabetes Care
-
Ascensia Diabetes Care
-
Sinocare
-
LifeScan
*Disclaimer: Major Players sorted in no particular order
Italy Self-Monitoring Blood Glucose Devices Market News
- January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.
- January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas Pulse included an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It was designed to be used with patients of all ages, including neonates and people in intensive care.
Italy Self-Monitoring Blood Glucose Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Component
- 5.1.1 Glucometer Devices
- 5.1.2 Test Strips
- 5.1.3 Lancets
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Abbott Diabetes Care
- 7.1.2 Roche Diabetes Care
- 7.1.3 LifeScan
- 7.1.4 Ascensia Diabetes Care
- 7.1.5 Bionime Corporation
- 7.1.6 Menarini
- 7.1.7 Rossmax International Ltd.
- 7.1.8 Arkray Inc.
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Abbott Diabetes Care
- 7.2.2 Roche Diabetes Care
- 7.2.3 LifeScan
- 7.2.4 Other Company Share Analyses
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityItaly Self-Monitoring Blood Glucose Devices Industry Segmentation
Self-monitoring of blood glucose is an approach used by diabetic patients to measure their blood sugar level themselves using a glucometer, test strips, and lancets. Based on the readings, patients can adjust or check the effect of their treatment. The Italy self-monitoring blood glucose devices market is segmented by components. The report offers the value (in USD) and volume (in units) for the above segments.
| Component | Glucometer Devices |
| Test Strips | |
| Lancets |
Italy Self-Monitoring Blood Glucose Devices Market Research Faqs
How big is the Italy Self-Monitoring Blood Glucose Devices Market?
The Italy Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 1.20 billion in 2024 and grow at a CAGR of 5.92% to reach USD 1.30 billion by 2029.
What is the current Italy Self-Monitoring Blood Glucose Devices Market size?
In 2024, the Italy Self-Monitoring Blood Glucose Devices Market size is expected to reach USD 1.20 billion.
Who are the key players in Italy Self-Monitoring Blood Glucose Devices Market?
Roche Diabetes Care, Abbott Diabetes Care, Ascensia Diabetes Care, Sinocare and LifeScan are the major companies operating in the Italy Self-Monitoring Blood Glucose Devices Market.
What years does this Italy Self-Monitoring Blood Glucose Devices Market cover, and what was the market size in 2023?
In 2023, the Italy Self-Monitoring Blood Glucose Devices Market size was estimated at USD 1.13 billion. The report covers the Italy Self-Monitoring Blood Glucose Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Italy Self-Monitoring Blood Glucose Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Italy Self-Monitoring Blood Glucose Devices Industry Report
Statistics for the 2024 Italy Self-Monitoring Blood Glucose Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Italy Self-Monitoring Blood Glucose Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
